Researchers at the University of Virginia Brain Institute and UVA School of Medicine will conduct a trial to see if the ...

EpiScalp could significantly reduce false positives and spare patients from medication side effects, driving restrictions, ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

A new tool called EpiScalp developed by researchers at Johns Hopkins University could reduce epilepsy misdiagnoses by up to ...

Idiopathic epilepsy is the most common medical neurologic disorder of dogs and is reported to affect one in every 100 dogs.

Advanced, injectable neural robots present a promising new epilepsy treatment. The project, called NEUROBOT, is one of 18 which will share in £69m over four years in new funding announced today from ...

Jan. 22, 2025 — Doctors could soon reduce epilepsy misdiagnoses by up to 70% using a new tool that turns routine electroencephalogram, or EEG, tests that appear normal into highly accurate ...

Misdiagnosis of epilepsy could be reduced by up to 70 per cent using EpiScalp, a new tool that turns routine ...

Bright Minds Biosciences (DRUG) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi.Invest with Confidence: ...

Certain proteins found in the human brain have long been known to be critical to controlling how brain cells communicate with ...